Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

Show more authors
+ 21
S Peters
U Dafni
M Boyer
D De Ruysscher
C Faivre-Finn
E Felip
P Garrido
N Girard
M Guckenberger
J Haanen
C Le Pechoux
F Mornex
M Ozsahin
L Paz-Ares
D Planchard
D Raben
S Ramalingam
M Reck
E Smit
R Stahel
A Stenzinger
C Swanton
S Vallone
M C Garassino

More about this publication

Annals of oncology : official journal of the European Society for Medical Oncology

Volume 30
Issue nr. 2
Pages 161-165
Publication date 01-02-2019

Full text links

Publisher website (DOI) 10.1093/annonc/mdy553
Europe PubMed Central 30624547
Pubmed 30624547

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.